DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Sai Parenterals Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 1 hr ago·8 Oct 2026, 8:49 am

Sai Parenterals

Sai Parenterals Limited has informed stock exchanges that it has obtained a Certificate under SEBI's (Depositories and Participants) Regulations, 2018. This regulatory document confirms that the company's shareholding pattern is accurate and compliant with current market rules.

For investors, this development is largely procedural. It ensures transparency regarding the ownership structure of the company's shares, which is a standard requirement for listed entities. This step helps maintain trust in the company's financial reporting and adherence to regulatory norms.

Investors should note that this is a routine compliance update. There are no immediate operational or financial implications arising from this filing. Market participants will continue to monitor the company's performance and any future regulatory disclosures.